Immune-Related Adverse Events after Immune Checkpoint Blockade-Based Therapy are Associated with Improved Survival in Advanced Sarcoma
Demographics (1)
- SEX - Biological sex (phv00530693.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00530699.v1.p1)
Other (19)
- 1st irAE - Type of first immune-related adverse event (irAE) of any grade (phv00530701.v1.p1)
- 2nd irAE - Type of second immune-related adverse event (irAE) of any grade (phv00530702.v1.p1)
- ANALYTE_TYPE - Analyte type (phv00530706.v2.p1)
- BODY_SITE - Body site of origin of sample (phv00530705.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00530692.v1.p1)
- Grade >= 3 irAE - Type of immune-related adverse event (irAE) of grade three or higher (phv00530703.v1.p1)
- HISTOLOGICAL_SUBTYPE - Tissue subtype of sample (phv00530709.v2.p1)
- HISTOLOGICAL_TYPE - Tissue type of sample (phv00530708.v2.p1)
- IS_TUMOR - Tumor status (phv00530707.v2.p1)
- PAIRED_SAMPLE - Sample ID of paired tissue collected from the same patient at a different timepoint, if applicable (phv00544316.v1.p1)
- SAMPLE_ID - Sample ID (phv00530704.v2.p1)
- SAMPLE_ID - Sample ID (phv00530697.v2.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00530695.v1.p1)
- SUBJECT_ID - Subject ID (phv00530698.v1.p1)
- SUBJECT_ID - Subject ID (phv00530691.v1.p1)
- SUBJECT_ID - Subject ID (phv00530696.v2.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00530694.v1.p1)
- TIMEPOINT - Timepoint of sample collection (phv00544315.v1.p1)
- Trial - Clinical trial (phv00530700.v1.p1)